12:43 PM EDT, 07/02/2024 (MT Newswires) -- Annovis Bio ( ANVS ) shares surged 25% in recent trading Tuesday after an advance study showed buntanetap was effective in improving motor, non-motor and cognitive functions in patients with early Parkinson's disease.

Buntanetap halted cognitive decline in all enrolled patients, while patients with mild dementia showed improved cognition, the company said.

Annovis said the drug showed improvement in motor and non-motor functions in patients diagnosed with Parkinson's disease more than three years and patients with postural instability and gait difficulty.

Results from the study show that buntanetap met both primary and secondary endpoints in specified subgroups.

Price: 6.57, Change: +1.30, Percent Change: +24.67